A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

This study was intended to assess how well inhaled NVA237 opens up the airways of patients with mild, moderate or severe COPD over a 24 hour period after a 14 day treatment period.

Key facts

Study ID

NCT00856193

Run by

Novartis

People needed

33

Starts

2009-02-01

Expected to finish

2009-05-01

Last updated by the study team

2016-09-14

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female aged greater than 40 years with COPD Current or ex-smokers

You may not qualify if…

• Cardiac (heart) disorders, history of asthma, requiring oxygen therapy. Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Spartanburg Medical Research — Spartanburg, South Carolina, United States
• Harrison Clinical Research Deutschland GmbH — Albrechtstrasse 14, Munich, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.